Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022.
Krystal Biotech, Inc. (NASDAQ:KRYS) s latest quarter saw the firm beat analyst estimates, as it posted -$0.17 in earnings per share for its third fiscal quarter.
In times of economic downturns, the beauty industry remains resilient, as consumers still like to splurge on beauty and skincare regimen, even if it might be in moderation.